Poseida Therapeutics Shares Leap on Astellas Investments
By Colin Kellaher
Poseida Therapeutics shares surged Monday after the clinical-stage biopharmaceutical company said it would receive a $50 million investment from Astellas that will help support its strategic and operational plans.
Shares of the San Diego company were recently changing hands at $2.56, up about 57%.
Poseida said Astellas is taking an 8.8% stake in the company by investing $25 million for more than 8.33 million shares at $3 apiece, an 84% premium to Friday's closing price of $1.63.
Astellas is also paying $25 million for a right of exclusive negotiation and first refusal to license P-MUC1C-ALLO1, Poseida's allogeneic CAR-T cell therapy in development for multiple solid tumor indications.
Posieda said the investment, along with cost-control measures it has implemented, extend its cash runway into early 2025.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 07, 2023 10:26 ET (14:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track